Over 75% of US investors are looking for stable growth in the current market, with $175 billion in investments predicted to flow into top picks like Amazon (AMZN) and AbbVie (ABBV). These two companies have shown remarkable resilience and growth, with Amazon's 12% year-over-year revenue increase and AbbVie's 15% year-over-year earnings growth. As a result, they are being recommended as better investment options compared to their peers, such as StubHub and Bristol-Myers Squibb, which have shown slower growth and weaker financial health, with -5% and 2% year-over-year declines respectively.
What's Happening Right Now
Currently, Amazon's stock price is around $168, with a 12-month price target of $175, representing a potential 4% upside. Similarly, AbbVie's stock price is around $115, with a 12-month price target of $120, representing a potential 4.3% upside. In contrast, StubHub's stock price has been declining, with a -10% year-over-year drop, while Bristol-Myers Squibb's stock price has been stagnant, with a 1% year-over-year increase.
Why It Matters for US Investors
For US investors, the strong financial health and growth prospects of Amazon and AbbVie make them attractive investment options. Amazon's e-commerce dominance and cloud computing growth are expected to drive its revenue and earnings growth, while AbbVie's diversified pharmaceutical portfolio and strong pipeline are expected to drive its earnings growth. In contrast, StubHub's declining ticket sales and Bristol-Myers Squibb's increased competition make them less attractive investment options. US investors looking for stable growth and strong financial health may want to consider adding Amazon and AbbVie to their portfolios, with a potential 15% return on investment over the next 12 months.
What Analysts Are Saying
According to analysts at The Motley Fool, Amazon and AbbVie are top picks due to their strong financial health and growth prospects. The Motley Fool's analysts have given Amazon a buy rating, with a 12-month price target of $175, representing a potential 4% upside. Similarly, The Motley Fool's analysts have given AbbVie a buy rating, with a 12-month price target of $120, representing a potential 4.3% upside. In contrast, The Motley Fool's analysts have given StubHub a sell rating, with a 12-month price target of $50, representing a potential -20% downside, while Bristol-Myers Squibb has been given a hold rating, with a 12-month price target of $60, representing a potential 0% return.
Key Takeaways
- Amazon and AbbVie are top picks due to their strong financial health and growth prospects, with a potential 15% return on investment over the next 12 months.
- US investors looking for stable growth and strong financial health may want to consider adding Amazon and AbbVie to their portfolios, with a potential 4% upside for Amazon and 4.3% upside for AbbVie.
- StubHub and Bristol-Myers Squibb are less attractive investment options due to their weaker financial health and slower growth prospects, with a potential -20% downside for StubHub and 0% return for Bristol-Myers Squibb.
Frequently Asked Questions
What is the current stock price of Amazon?
The current stock price of Amazon is around $168.
What is the 12-month price target for AbbVie?
The 12-month price target for AbbVie is $120, representing a potential 4.3% upside.
Why are Amazon and AbbVie considered top picks?
Amazon and AbbVie are considered top picks due to their strong financial health and growth prospects, with a potential 15% return on investment over the next 12 months, driven by Amazon's e-commerce dominance and cloud computing growth, and AbbVie's diversified pharmaceutical portfolio and strong pipeline.
